Published in final edited form as:

Clin Pharmacol Ther. 2015 June ; 97(6): 616–627. doi:10.1002/cpt.118.

Cannabinoid abuse and addiction: Clinical and preclinical findings

Leigh V. Panlilio, Steven R. Goldberg[†], and Zuzana Justinova

Preclinical Pharmacology Section, Behavioral Neuroscience Research Branch, Intramural Research Program, National Institute on Drug Abuse, NIH, DHHS, Baltimore, Maryland, USA

Keywords

Cannabis; marijuana; THC; cannabinoids; self-administration; primate; rat; relapse; abstinence

Introduction

Cannabinoid abuse disorders represent a widespread public health issue, but there are no approved medications for their treatment. This review describes efforts to understand the mechanisms of cannabinoid abuse and its adverse effects, to identify molecular targets for pharmacotherapy, and to evaluate potential treatments in human volunteers and animal models of cannabinoid reward, withdrawal, and relapse.

Cannabis and cannabinoids

Cannabis is typically used in the form of marijuana (made from dried leaves and flowers of *Cannabis sativa*) and hashish (made from resin glands of marijuana). In the last decade, synthetic cannabinoids, sprayed onto herbal substrates and marketed under names such as Spice or K2, have become increasingly prevalent. Like cannabis, these “spice drugs” are typically administered by combustion and inhalation.¹ Fifteen synthetic cannabinoids are currently classified as Schedule I substances, indicating high abuse potential but no approved medical use under the US Controlled Substance Act.² However, the active ingredients of spice drugs (e.g., JWH-018, JWH-073, JWH-200, and CP47,497) are not listed by the manufacturers and are constantly changing in response to legislature, making regulation and enforcement difficult.

Marijuana legalization efforts have been increasingly successful in the United States. At the time of publication, 23 states and the District of Columbia have legalized prescription use of marijuana for treatment of various medical conditions, and 5 states and the District of Columbia have also legalized marijuana for recreational use. Despite these changes in state laws, cannabis remains a Schedule I substance under federal law. In 2013, cannabis was the illicit drug with the largest number of persons reporting past year use.³ Although it remains

Correspondence: Z Justinova, Preclinical Pharmacology Section, Intramural Research Program, National Institute on Drug Abuse, NIH, DHHS, 251 Bayview Blvd., Baltimore, Maryland 21224, USA; Tel: +1 443 740 2522, Fax: +1 443 740 2733, zjustino@intramural.nih.gov.

[†]In memoriam

to be seen, it seems likely that marijuana legalization will increase the already large number of people using and becoming dependent on cannabis.

Cannabis contains over 100 phytocannabinoids, but the pharmacological effects of many of them are not known. The main psychoactive component of cannabis is delta-9-tetrahydrocannabinol (THC; see Figure 1), which acts as a partial agonist at cannabinoid CB₁ and CB₂ receptors.⁴ The actions of THC at CB₁ receptors are considered to be critical for its psychoactive effects, but THC also acts at peroxisome proliferator-activated receptors (PPAR) and GPR55 receptors.⁴ Most cannabis preparations also contain cannabidiol (CBD), a cannabinoid that exerts pharmacological effects via multiple mechanisms (e.g., CB₁, CB₂, serotonin 5-HT_{1A}, PPAR-gamma, opioid, and vanilloid TRPV1 receptors, modulation of endocannabinoid metabolism and intracellular calcium metabolism) that are not yet fully understood.^{4, 5} CBD has been shown to have antipsychotic, anticonvulsive, neuroprotective and anxiolytic effects and is believed to offset some of the undesirable psychotropic effects of THC.^{4, 5} Cannabis also contains over 200 other chemicals, including terpenoids and essential oils, some of which might have pharmacological effects of their own or modulate the effects of other cannabis ingredients including THC.

The potency of cannabis products (expressed as THC content) has increased steadily over the last four decades. The average THC concentration in confiscated marijuana in the United States increased from 1–2% in the 1970s to 10–11% in 2010.⁶ Reports from the Netherlands and other European countries show that THC content in cannabis can now reach close to 20%.⁷ Cannabis selectively bred for high THC content often has very low CBD content, and its use has been associated with higher occurrence of mental health problems among users (e.g., induction of psychosis in susceptible users, anxiety, panic attacks). Research in cannabis users demonstrate that cannabis with low CBD content produces stronger reinforcing effects and higher ratings of liking and wanting the drug, which could potentially make low-CBD cannabis more addictive.⁵ Unlike THC, which is a partial agonist at CB₁ receptors,⁴ many synthetic cannabinoids are high-efficacy full agonists at CB₁ receptors.⁸ Furthermore, synthetic cannabinoids are not typically mixed with CBD. Probably for these and other reasons, including high variability of the potency of spice drugs even within samples from the same package, spice drugs produce more frequent and more severe adverse effects than cannabis^{7–9}, and spice drug users have a 30 times higher risk of seeking emergency room assistance compared to cannabis users.⁷

For further information on the topics discussed in this section, please see Supplementary Table 1, which also presents additional readings related to most of the other sections of this review.

Cannabinoid use, abuse and dependence in humans

Acute effects of cannabinoids

Inhalation of cannabis smoke is the generally-preferred route of administration because it produces rapid effects and, unlike oral ingestion, can be easily titrated to a desired level of effect. Acute effects last for approximately 2–3 hours and are often described as a pleasant and relaxing experience. The unique mixture of depressant and stimulant effects is

characterized by euphoria, easy laughter, talkativeness, sedation, distortion of time perception, increased perception of external stimuli, and memory lapses. Users typically experience increased appetite, dry mouth, tachycardia and blood pressure increase, and bronchodilation. A sense of well-being may alternate with dysphoria. The effects are individually variable and are influenced by the amount of cannabis (i.e., the dose of THC), first-time vs. repeated use, preexisting vulnerability to mental illness, and personality traits.¹⁰ Acute adverse effects of cannabis use include dysphoria, anxiety, panic reactions, paranoia, and sometimes positive psychotic symptoms (e.g., auditory hallucinations, disorganized thought, delusions of persecution).^{10–12} Cannabis also impairs short-term memory and attention, judgment, motor coordination, performance of complex mental tasks, and reaction time^{10, 12}, which can limit the ability to drive a car and operate machinery. Acute cannabis exposure doubles the risk of motor-vehicle accident, and THC blood levels of 2–5 ng/mL are associated with substantial driving impairment.¹³

At high doses, the frequency and seriousness of undesired acute effects of cannabis increases, especially in naïve users.¹² Many short-term symptoms can manifest, such as depersonalization, derealization, disorientation, delusions, hallucinations, paranoid ideas, disordered thinking, irrational panic, psychomotor agitation, and emotional lability.^{10, 11} Toxic or organic psychosis can be induced in people without history of severe mental illness. These problems generally resolve within a week of abstinence.

Many of the acute effects of synthetic cannabinoids (SCBs) are similar to those of cannabis and include euphoria, a feeling of well-being, relaxation, perceptual alterations, as well as mild memory and attention impairments.⁸ Users report that some SCBs have a shorter duration of effect and an earlier peak effect than cannabis, but pharmacokinetic profiles differ widely across SCBs, and the effects of various SCBs can last anywhere between 1 to 6 hrs.⁷ Toxicity profiles of SCBs are similar to that of high doses of THC, but SCBs are more potent than THC, and SCB-laced spice drugs are highly variable in SCB concentration, which may lead to variable and unpredictable effects, as well as increased likelihood of serious side effects associated with accidental overdose.⁷ The use of SCBs can be followed by acute negative symptoms like paranoia, delusions, hallucinations, anxiety, panic attacks, suicidal ideation, extreme agitation, nausea, emesis, seizures, dizziness, ataxia, nystagmus, drowsiness, as well as cardiovascular effects like hypertension, tachycardia, chest pain, or arrhythmias.^{7, 8} Sixty percent of SCBs overdoses occur in people under 25 years of age, and inexperienced and/or young users are particularly sensitive to the toxic effects of SCBs.⁷ Spice drugs are more likely than cannabis to provoke psychosis in predisposed persons or schizophrenics, possibly spice drugs do not contain CBD, which might have protective effects.⁷

Long-term effects of cannabinoids

Although it is difficult to establish causality by cannabinoid exposure in epidemiological studies, long-term cannabinoid use is associated with significant neurobiological, psychosocial, and general health problems.^{10, 14} Regular cannabinoid use, particularly when started in adolescence, is associated with addiction, lasting cognitive impairment (e.g., lower IQ), poor educational outcome, diminished life satisfaction and achievement, and increased

risk of psychotic disorders.^{14, 15} The brain (including the endocannabinoid system) undergoes active developmental changes during adolescence and is more vulnerable to adverse effects of long-term exposure to THC.^{14, 15} Functional and structural changes in the brains of marijuana smokers have been demonstrated.^{14, 16} For example, adults who smoked marijuana regularly during adolescence have decreased functional connectivity in brain regions important for learning, memory, executive functioning, and processing of habits and routines, which might be responsible for impairments such as lowered IQ.^{14, 16} Recently, Volkow and colleagues¹⁷ showed that marijuana users have reduced brain reactivity to dopaminergic stimulation, and that this change might contribute to their negative emotionality (increased stress reactivity and irritability) and drug craving.

Cannabis addiction develops with heavy chronic use, and involves symptoms such as difficulty controlling or limiting use even in the face of adverse effects on their daily lives. The lifetime risk of dependence (defined by DSM criteria) among all cannabis users is estimated at about 9% and increases to 1 in 6 among those who initiate use in adolescence.^{14, 15, 18} Addiction is a complex disease determined by many factors, including genetics. Research on genetic variants associated with cannabis addiction is limited compared to nicotine and alcohol. So far, single nucleotide polymorphisms in *CNR1* and *FAAH* (fatty acid amide hydrolase) genes have been linked to cannabis addiction phenotypes.¹⁹ In a recent study, functional-connectivity magnetic resonance imaging demonstrated that cannabis users with genetic variation in *CNR1* (rs1406977 G carriers) had greater functional connectivity in the left ventrolateral prefrontal cortex and reduced working memory behavioral accuracy compared with other groups.²⁰

Reliable information on doses of cannabis and patterns of use in regular users are often difficult to obtain. “Heavy” or “regular” use has been defined in epidemiological studies as daily or near daily use.¹⁵ This type of use over years carries high risks of adverse health effects. Recently, Hughes and colleagues²¹ reported on characteristics of marijuana use in a group of participants that used marijuana more than 5 times a week. They found that, within this population, daily users tend to use multiple times per day, use multiple modes of administration, show more signs of intoxication, and have high rates of tobacco use. Co-use of tobacco and cannabis is common, probably due to factors such as the relatively easy availability of both drugs and the common route of administration. Ninety percent of cannabis users report being cigarette smokers at some point during their lifetime¹⁹, and co-use, which is often long-term, increases negative health consequences (e.g., chronic bronchitis). Simultaneous cessation of tobacco and cannabis use leads to a more challenging withdrawal syndrome that can have implications for addiction treatment.¹⁹ Persistent tobacco use is associated with a poorer response to treatment for cannabis use disorders, and vice versa.^{19, 22}

Cannabis use disorder

From a clinical perspective, DSM-V (Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition 2013) presents an improved approach to substance use disorders by combining abuse and dependence criteria into one disorder, and by adding “craving or a strong desire or urge to use the substance” as a criterion for substance use disorder.²³ DSM-

V now recognizes a Cannabis-Related Disorders category that includes cannabis use disorder, cannabis intoxication, cannabis withdrawal, other cannabis-induced disorders, and unspecified cannabis-related disorder. The DSM-V diagnostic criteria for Cannabis Use Disorder are listed in Table 1. Relatively little is known about the development and natural course of cannabis use disorders in the general population. Similarly to other drug addictions, cannabis addiction is a chronic disorder characterized by repeated attempts to quit followed by relapse. Repeated exposure to cannabinoids results in tolerance to the subjective and performance-impairing effects of cannabis and also induces physical dependence that is characterized by a withdrawal syndrome upon cessation of drug use.²⁴

Cannabis withdrawal has over time gained recognition as a clinically significant phenomenon.^{25, 26} Due to overwhelming preclinical, clinical, and epidemiological evidence cannabis withdrawal has been added to DSM-V and is included as one of the criteria for cannabis use disorder.²³ Symptoms of cannabis withdrawal are described in Table 2. Cannabis withdrawal is associated with functional impairment of normal daily activities and contributes to relapse.^{24, 26, 27} Relapse rates observed for cannabis use disorders are comparable to those for other abused drugs, and only 15–37% of patients undergoing psychotherapeutic and pharmacological interventions achieve continued abstinence.²² Besides withdrawal-induced craving, other precipitators of relapse to drug use are stress and cue-elicited craving. Exposure to marijuana-related cues increases craving in dependent individuals and is linked to increased brain responses in the limbic amygdala, hippocampus, and ventral striatum.²⁸

Other consequences of heavy chronic cannabis use can be depersonalization and amotivational syndrome, although it is unclear whether the latter involves a change in motivation as opposed to a change in attention or simply a state of intoxication.^{10, 11} There are high rates of comorbidity between cannabis use other psychiatric disorders, including psychosis (schizophrenia), depression, anxiety disorders, bipolar disorder, certain personality disorders, and other substance use disorders.^{10–12} Heavy cannabis use can also cause neurocognitive deficits that persist for several days or weeks following cessation of cannabis intake, and memory and attention impairments may persist and worsen with increasing years of use and with the initiation of use during adolescence.¹⁴ Consequences of cannabis use also manifest in the respiratory, digestive, cardiovascular, and reproductive systems.^{10, 12}

Synthetic cannabinoids

Since spice drugs are a relatively recent phenomenon, the long-term psychopathological and physical effects of SCBs are not well known. Tolerance to SCBs develops quickly, and chronic SCB users could meet criteria for cannabis use disorders.^{1, 7} Cases of withdrawal syndrome have been reported with the following symptoms: craving, restlessness, nightmares, tachycardia, hypertension, nausea, sweating, headaches, muscle twitches, severe anxiety, chest pains, cramping and chills.^{8, 9}

Treatment of cannabis use disorders: Clinical and human laboratory studies

Over the past twenty years, there has been a steady increase in the number of regular cannabis users in the US; in the year 2013, over 8 million people were using twenty or more times per month, and more people (about 845,000) were treated for cannabis use than for any other illicit substance.³ There are currently no approved medications for treating cannabis use disorders. The most successful psychotherapeutic models include cognitive-behavioral therapy, motivational enhancement therapy, contingency management, and family-based therapies.^{29, 30} However, nonresponse and relapse rates among patients remain high (70%), and there has been a call for the development of effective pharmacotherapies to complement the psychosocial therapies.²⁹ Studies of potential medications in humans have focused mainly on promoting the initiation of abstinence, reducing withdrawal symptoms, and preventing relapse.

Among potential medications that have been tested, the most promising results have been obtained with replacement therapy using CB₁ agonist medications. Dronabinol (Marinol) is a synthetic form of THC approved for treatment of nausea associated with chemotherapy and for use as an appetite stimulant for AIDS or cancer patients. Dronabinol was tested in several within-subject, placebo-controlled human-laboratory studies. Reduction of withdrawal symptoms was observed, but no effect on cannabis self-administration or relapse was found.³⁰ These effects were confirmed by a large clinical trial with dronabinol in combination with behavioral therapies.³¹ Recently, a human laboratory study with nabilone, a synthetic, highly-bioavailable THC analogue with clinical indications similar to those of dronabinol, showed promise for reduction of withdrawal symptoms and relapse.³² An alternative to use of direct CB₁ agonists is pharmacological inhibition of the enzymes (FAAH and monoacylglycerol lipase) that degrade the endogenous CB₁ agonists anandamide and 2-arachidonoylglycerol (2-AG), respectively. These inhibitors enhance and prolong the effects of endocannabinoids when and where they are released in the brain, and might therefore be useful as a replacement therapy or for relieving withdrawal. Currently, the FAAH inhibitor PF-04457845 is in clinical testing for efficacy in treatment of marijuana withdrawal. PF-04457845 was well tolerated in previous clinical trials³³, and no cannabis-like adverse effects have been reported.

Drugs acting as antagonists or antagonist/inverse agonists at CB₁ receptors (like rimonabant) represent an alternative approach to the treatment of cannabis addiction, by directly blocking the subjective and reinforcing effects of THC. Initial findings were promising as rimonabant attenuated the subjective and physiological effects of smoked marijuana.³⁴ Unfortunately, rimonabant has been withdrawn from clinical use due to psychiatric side effect (anxiety, depression, suicidality).³⁵ As noted below, it is possible that CB₁ antagonists that lack inverse-agonist effects might be safer than rimonabant but still block the effects of THC.

Functional, bidirectional interactions between the endogenous cannabinoid and opioid systems has been demonstrated in numerous studies. Treatment with mu-opioid antagonists such as naltrexone represents a possible approach to reducing the reinforcing effects of

THC.³⁶ However, acute naltrexone administration can increase the positive subjective effects of cannabis in marijuana smokers.³⁷

A number of antidepressants, anxiolytics, and antipsychotics have been assessed for treatment of cannabis addiction in humans, with little success. These include escitalopram, atomoxetine, fluoxetine, venlafaxine, buspirone, bupropion, nefazodone, mirtazapine, and quetiapine.²⁹ Promising effects were observed with the α_2 -adrenergic receptor agonist lofexidine, especially in combination with dronabinol³⁸; the combination of dronabinol and another α_2 -adrenergic receptor agonist, clonidine, is currently being studied in cannabis-dependent schizophrenics (ClinicalTrials.gov). The antiepileptic gabapentin has also shown promise in attenuating withdrawal severity and reducing cannabis use.³⁹ N-acetylcysteine, an over-the-counter supplement that might work by normalizing glutamate activity, also decreased cannabis use.⁴⁰ Cannabidiol alone or in combination with THC (Sativex) is currently under investigation in several clinical trials for management of cannabis use disorders (ClinicalTrials.gov). A recent meta-analysis of controlled trials of pharmacotherapies for cannabis dependence led the authors to conclude that the available evidence is limited at this point, but that CB₁ agonist therapy shows the most promise, followed by gabapentin and N-acetylcysteine.⁴¹

Neurobiology of cannabinoid addiction

Much of the information available concerning the neurobiology of addiction and the effects of cannabinoids has been obtained with animal research, as described in the following sections of this paper. The mesolimbic dopaminergic system has a well-established role in the reinforcing effects of drugs of abuse, including cannabinoids, with the nucleus accumbens and ventral tegmental area (VTA) regions playing major roles. In humans, low dopaminergic tone during withdrawal and reduced behavioral and striatal reactivity to the dopaminergic stimulation in marijuana abusers have been linked to negative emotionality and addiction severity and craving.¹⁷ Cannabinoid CB₁ receptors are located presynaptically in the brain reward circuitry and their activation inhibits neurotransmitter release (see Figure 1). Depending on the presynaptic signal (glutamatergic or GABAergic), activation of CB₁ receptors by exogenous or endogenous cannabinoids can suppress or facilitate postsynaptic response and modulate dopamine release. In this process, the endocannabinoids (anandamide or 2-AG) act as retrograde messengers, as they are released on demand from postsynaptic neurons. Thus, the endocannabinoid system can modulate dopaminergic reward circuits, which suggests that endocannabinoids also play a major role in the mechanisms underlying drug addiction.

Prolonged exposure to cannabinoids causes complex adaptations in the brain's neuronal circuits and their components. Changes have been uncovered in synaptic transmission and plasticity, CB₁ receptor density and function, signaling cascades (e.g., MAPK/ERK1/2), and gene expression after chronic cannabinoid treatment. Detailed discussion of the many findings concerning the neurobiology of cannabis addiction, dependence, and withdrawal are beyond the scope of this review, so we recommend the following reviews for further reading: Fratta and Fattore⁴²; Hoffman and Lupica⁴³; Covey et al.⁴⁴.

Animal models of cannabinoid reward, relapse and withdrawal

Compared to drug classes such as opioids, stimulants, and depressants, cannabis is widely recognized as having less potential to produce dependence and addiction. However, cannabis and synthetic cannabinoids do produce these effects, and techniques developed for studying drugs such as cocaine and heroin have proven useful in modeling these effects in animals. At least initially, addictive drugs are used because they have rewarding effects, producing euphoria and reinforcing the drug-taking behavior. Through the processes of conditioning and learning, specific cues in the environment gain control of behavior, activating and guiding complex sequences of actions required to obtain, prepare, and self-administer the drug. Over time, this behavior can become increasingly habitual and resistant to change. Even after a long period of abstinence, re-exposure to the drug or drug-related cues can induce relapse.

Drug self-administration

Drug self-administration is the preeminent animal model of drug use because it bears a close resemblance to human drug-taking and involves similar forms of conditioning and learning, with at least partial congruence of the underlying neural circuitry. When allowed to self-administer a drug by performing a simple response such as pressing a lever, laboratory animals will self-administer most of the same drugs as humans. However, in early studies in which animals were allowed to self-administer THC, they did not develop the stable patterns of intake seen in regular cannabis users. Eventually, reliable procedures for obtaining robust intravenous THC self-administration in squirrel monkeys were developed in our laboratory⁴⁵ using relatively low doses, within the same range self-administered by human cannabis smokers. Several laboratories have also successfully obtained intravenous self-administration of the synthetic cannabinoid CB₁ agonist WIN 55,212-2 in rats^{46, 47} and mice⁴⁸.

The initial demonstration of THC self-administration in squirrel monkeys was performed in monkeys that had prior experience self-administering cocaine⁴⁵, but subsequent work showed that THC is readily self-administered by monkeys with no prior drug experience.⁴⁹ The dose-effect function for THC self-administration has the inverted-U shape typical of other drugs of abuse (Figure 2), with low doses maintaining little or no responding (presumably due to weak reinforcing effects), moderate doses maintaining high rates of responding (presumably due to strong reinforcing effects), and high doses maintaining moderate to low responding (presumably due to strong reinforcing effects accompanied by satiating effects or behaviorally-disruptive side effects such as sedation).

THC self-administration is blocked by pre-treatment with the cannabinoid CB₁ antagonist rimonabant, suggesting that activation of CB₁ receptors is central to cannabinoid reward; the fact that rimonabant has this effect at doses that do not alter food or cocaine self-administration indicates that it selectively affects cannabinoid reward as opposed to producing a nonselective disruption of operant behavior.^{45, 50} Interpretation of this finding is somewhat complicated by the fact that rimonabant can also decrease the reinforcing effects produced by other drug classes (most notably nicotine) and the conditioned reinforcing effects of cues associated with these drugs; nonetheless, these findings make sense in light

of the hypothesis that CB₁ antagonists reduce the rewarding effects of drugs, drug-associated cues, and even non-drug reinforcers such as food because the endogenous cannabinoid system modulates the common reward system circuitry that underlies the effects of all these reinforcers. This interpretation is consistent with the finding that anandamide⁵¹ and 2-AG⁵², the main endogenously-occurring ligands for the CB₁ receptor, are self-administered by squirrel monkeys when they are offered as an intravenous solution (Figure 2).

The conditioned reinforcing effects of THC-associated cues have been studied in squirrel monkeys by using a second-order schedule.⁵⁰ In this procedure, every tenth lever-press response produces a brief illumination of a colored stimulus light; the first stimulus produced after 30 minutes is accompanied by intravenous infusion of THC. Under these conditions, the brief stimulus becomes a conditioned reinforcer, producing substantially higher and more persistent response rates than would occur if only the drug were presented. This chain of behavior guided by drug-associated cues provides a simplified model of the process by which environmental cues maintain complex sequences of drug-seeking behavior in the human drug-abuse environment. Discontinuation of the brief-stimuli produces an immediate 60–75% decrease of the THC-seeking response.

Reinstatement

Manipulations such as discontinuing delivery of THC and/or THC-associated cues can be used as part of the reinstatement model of relapse. This imposed abstinence causes drug seeking to drop to very low levels, at which point monkeys can be given an automatic, experimenter-delivered infusion of THC or another drug at the beginning of the session to see if it increases (i.e., primes) the drug-seeking response. Or, cues can be presented that previously signaled the availability of THC or were previously associated with THC. These drug-priming and cue-induced reinstatement procedures, respectively, model the relapse-triggering effects of drug re-exposure and cue re-exposure known to affect human drug users. Using these procedures, Justinova et al.⁵⁰ found that experimenter-administered infusions of THC, anandamide, or methanandamide (a long-acting form of anandamide) could reinstate THC seeking. Interestingly, morphine was also able to induce reinstatement of THC-seeking, but cocaine was not, consistent with rodent research indicating that the cannabinoid and opioid systems of the brain interact in a mutually-enhancing fashion⁵³. Also consistent with this hypothesis, the μ -opioid receptor antagonist naltrexone can decrease ongoing THC self-administration in monkeys.³⁶

Rodent procedures

Nonhuman primates are phylogenetically close to humans and provide an invaluable model of many human neurobiological systems. However, there is a wealth of knowledge and neuroscience techniques that have accrued from the study of rodents, and it is fitting that drug abuse research should involve rodents when they can provide a valid model of human behavior and physiology. It is unclear why THC does not maintain robust self-administration behavior in rodents, even when offered to rats that have been trained to self-administer the synthetic CB₁ agonist WIN 55,212-2.⁴⁷ But, the fact that rodents do self-administer WIN 55,212-2 allows them to be useful for modeling aspects of cannabis use that

are difficult or impossible to study experimentally in humans or nonhuman primates, such as initial acquisition of cannabis use and the effects of irreversible treatments such as genetic or intracranial manipulations. For example, Deiana et al.⁵⁴ found differences between three strains of rats in acquisition of WIN 55,212-2 self-administration. Studies with intracranial microdialysis in rats, which is essentially a nonreversible treatment, have shown that levels of dopamine in the shell of the nucleus accumbens increase during WIN 55,212-2 self-administration but not the core⁵⁵; this is not simply an artifact of motor activity since dopamine levels did not increase when WIN 55,212-2 delivery was discontinued, despite high levels of lever pressing. In pro-dynorphin knockout mice, the dose-response curve for WIN 55,212-2 self-administration was shifted to the left compared to wild-type controls, and the kappa-opioid antagonist nor-binaltorphimine enhanced acquisition of WIN 55,212-2 self-administration in wild-type mice.⁴⁸

Place conditioning—Alternative, less direct measures that have been used to assess reward-related effects of cannabinoids in rodents include place conditioning, drug discrimination, and microdialysis. In place conditioning, the effects of a drug are associated with one of two distinctive compartments of an apparatus, and the drug's vehicle (placebo) is associated with the other compartment. In a subsequent test, the rodent is allowed access to both compartments; a preference for the drug-associated compartment indicates that the features of that compartment have become conditioned reinforcers, which implies that the effects of the drug are reinforcing. One advantage of such place-conditioning procedures is that they are sensitive not only to reinforcing effects but also to aversive effects of a drug, which can lead to avoidance of the drug-associated compartment. There is some evidence that low doses of THC produce place preference in rats, and higher doses produce place avoidance. But, in most studies THC and WIN 55,212-2 have produced either conditioned place aversion or no preference for either compartment.

Aversive effects such as anxiety and panic also occur in human cannabis¹⁰ and spice drug⁸ users and therefore warrant further study in animal models. Some recent studies have suggested that aversive effects of THC might depend on noradrenergic signaling in the nucleus accumbens induced by CB₁ agonists⁵⁷, and that aversive effects can be attenuated or reversed in adolescent rats with prior cannabinoid exposure.⁵⁸ Exposing rodents to THC prior to the place-conditioning procedure can facilitate development of a preference for the THC-associated compartment, possibly because the first exposure is more likely to be aversive.⁵⁹ The tendency of rodents to show mainly aversive effects in place-conditioning studies with CB₁ agonists are consistent with their lack of robust THC self-administration, although it is not clear whether these aversive effects mask rewarding effects, or whether the rewarding effects in rodents are simply weak due to differences between their reward systems and those of humans and nonhuman primates.

Drug discrimination—In drug-discrimination procedures, subjects are trained to detect whether they have received a certain psychoactive drug. For example, in a typical procedure rats are trained in an apparatus with two levers; pressing one lever produces food pellets on days when the rat has been injected with THC prior to the training session, and pressing the other lever produces food pellets on days when the rat has been injected with placebo. When

the rat has learned to accurately detect THC, tests can be performed by injecting a novel test substance, a different dose of THC, or a combination of THC and another drug. The rat's choice of levers during the test indicates whether the test substance produces interoceptive effects similar to THC, some of which are presumably analogous to subjective effects such as drug "high" in humans. Many test drugs have been evaluated with this procedure, and it has proven to be highly selective. That is, test drugs that do not act at CB1 receptors do not produce THC-like interoceptive effects, even if the test drug has strong abuse potential; THC-like effects are only produced by full or partial CB₁ agonists, including anandamide and synthetic agonists found in spice drug preparations. So, even though drug discrimination does not directly measure reinforcement, it is logical to expect that novel drugs that produce interoceptive effects similar to those of THC could also have abuse potential and other adverse effects similar to those of THC. Testing with drug combinations indicates that nicotine can potentiate the effects of THC, possibly through nicotine-induced release of endogenous anandamide⁶⁰, and that morphine can also potentiate the effects of THC⁶¹; such effects could provide a mechanism for the reported enhancements in rewarding effects¹⁹ produced by co-users of cannabis and other drugs.

Intracranial and ex vivo Procedures—Intracranial microinjection and microdialysis procedures can provide information about brain areas and neurochemistry involved in cannabinoid reward. In a study of opioid-cannabinoid interactions in rats, microinjection of beta-endorphin into the VTA (but not the accumbens shell) potentiated the effect of THC in a drug discrimination procedure.⁶¹ In another study, Zangen et al.⁶² allowed rats to self-administer microinjections of THC directly into specific brain areas. They found that THC had reinforcing effects in the nucleus accumbens and ventral tegmental area (VTA), regions known to be involved in reward, but that it did not have reinforcing effects in the substantia nigra. Further testing with a place-conditioning procedure in which THC was microinjected into subregions of these areas indicated that THC had reinforcing effects in the posterior VTA and posterior shell of the accumbens, but not in the anterior VTA, medial accumbens or posterior accumbens. These findings suggest that systemically-administered THC does have rewarding effects in rodents, but that these effects are masked or counteracted by effects in brain areas that are not congruent with (or have a weaker influence in) human and nonhuman primate brains.

Microdialysis allows sampling of neurochemical levels in specific brain areas. Reward-related microdialysis research has focused mainly on the VTA and nucleus accumbens in rats. Extracellular dopamine levels in the shell of the nucleus accumbens are increased by systemic treatment with THC, WIN 55,212-2, or anandamide, or by direct injection of THC into the VTA or nucleus accumbens, and such effects are blocked by pretreatment with a CB₁ antagonist, an opioid antagonist, or a serotonin-specific reuptake inhibitor.

Ex vivo procedures, such as in brain slices containing VTA neurons, also provide insight into the neurophysiological underpinnings of cannabis reward and neuroadaptations to cannabinoid exposure. For example, THC increases the firing of *ex vivo* VTA dopamine neurons, but these cells show tolerance to the effects of THC if the rat was repeatedly exposed to THC *in vivo* (i.e., prior to dissection).⁴⁴ Nucleus accumbens glutamate neurons

show changes in synaptic plasticity after *in vivo* THC exposure, and this might underlie lasting effects of THC exposure, such as altering the rewarding effects of other drugs.⁴³

Withdrawal

Chronic cannabis users typically experience unpleasant withdrawal symptoms when use is discontinued. These symptoms are much less severe than those associated with withdrawal from chronic opioid or depressant use, but aversive enough to encourage continued cannabis use and interfere with cessation attempts in some individuals. Animal models of cannabis withdrawal typically involve automatic exposure to THC, as opposed to self-administration. As in humans, the effects induced by simply discontinuing exposure in animals are not severe and can be hard to detect, probably due to the slow elimination of lipophilic compounds like THC from the brain. However, investigation of the mechanisms of withdrawal can be facilitated by using precipitated withdrawal procedures. In these procedures, withdrawal symptoms are precipitated by administering a CB₁ antagonist to rats that have received THC exposure for periods as short as four days⁶³; these symptoms include scratching, face rubbing, licking, wet-dog shakes, arched back and ptosis. Like humans undergoing abstinence-induced cannabis withdrawal, rats undergoing precipitated THC withdrawal show sex differences in severity of symptoms.⁶⁴ Precipitated withdrawal effects can also be observed as a disruption of learned behavior such as food-reinforced lever pressing.⁶⁵ In rhesus monkeys, drug discrimination has been used to model mild cannabis withdrawal by training subjects to distinguish between a low dose of THC with versus without a dose of the CB₁-antagonist rimonabant.⁶⁶ When vehicle was substituted for the usual THC administration in these monkeys but no rimonabant was given, they responded on the rimonabant-appropriate lever; when the CB₁ agonists WIN 55,212-2 or CP 55,940 were given instead of THC and no rimonabant was given, the monkeys responded as if they had received THC. However, in these tests rimonabant given after WIN 55,212-2 failed to reverse the effects of WIN 55,212-2, suggesting that non-CB₁ effects of WIN 55,212-2 (and possibly other synthetic cannabinoid agonists) are relevant to their subjective effects.

Since the withdrawal signs induced by cannabinoid antagonists in THC-dependent rats are not observed in THC-naïve control rats, they appear to be due to development of tolerance and other neuroadaptations in response to repeated THC exposure. Tolerance and dependence develop after daily exposure to THC or synthetic cannabinoids for periods as short as 3–14 days. Findings in rodents suggest that tolerance is due to downregulation of CB₁ receptors, and that aversive withdrawal symptoms involve increases in corticotropin-releasing hormone and decreases in dopamine signaling.

Gateway effects

Animal models provide a means of objectively studying the effects of THC exposure under controlled conditions. Repeated exposure to THC can have effects on behavior that last well beyond the last exposure, altering the effects of other drugs administered weeks or months after THC exposure is discontinued. Compared to vehicle-exposed controls, rats with a history of THC exposure have higher levels of intake when allowed to self-administer heroin.⁶⁷ A history of THC exposure decreased the reinforcing effects of cocaine⁶⁸, but

increased the reinforcing effects of nicotine.⁶⁹ The latter finding could be important because nicotine is normally a much weaker reinforcer than cocaine or heroin, but difficult to quit once regular use is established. Although animal models have not been used to evaluate the possibility that prior or simultaneous exposure to drugs such as nicotine and alcohol alter the reinforcing effects of cannabis, this is an area that deserves attention because it might provide insight into the mechanisms underlying the common gateway-like progression from alcohol and tobacco use to cannabis use and then to drugs such as cocaine and heroin.

Preclinical findings concerning potential medications for cannabis use disorders

There are currently no medications approved for the treatment of cannabis dependence, despite the fact that there is high demand for treatment and a clear need for more effective treatment options. Animal models of cannabinoid reward and relapse provide a means of identifying potential molecular targets for the development of pharmacotherapies that could be worth testing in humans. Four such targets have been pursued in the squirrel monkey model of cannabis abuse but that have not yet been tested in clinical trials are: cannabinoid antagonism, opioid antagonism, adenosine antagonism, and modulation of $\alpha 7$ nicotinic receptors.

Cannabinoid antagonism

As mentioned above, treatment with CB₁ antagonists such as rimonabant can block the rewarding effects of THC in animals and humans; monkeys treated with rimonabant self-administer very few THC infusions and show resistance to the relapse-inducing effects of re-exposure to THC and THC-associated environmental cues.^{45, 50} However, it should be noted that monkeys quickly resume THC self-administration when rimonabant is discontinued; this has been a general finding with all pharmacological treatments that block the rewarding effects of drugs. Also, rimonabant has the potential to precipitate withdrawal symptoms in THC-dependent individuals, which could potentially lead to noncompliance if it were prescribed as a treatment for cannabis use disorder. Furthermore, when rimonabant was prescribed as a treatment for obesity, it was associated with depression-like side effects and was subsequently withdrawn from the market.³⁵ However, it is possible that the adverse effects of rimonabant are due to its inverse-agonist properties, in which case a neutral CB₁ antagonist devoid of these properties might be both safe and effective, but this remains to be seen. If so, it might be expected that CB₁-antagonist treatment for cannabis dependence would parallel opioid-antagonist treatment for opioid dependence, in that it would be helpful as an adjunct to psychotherapy in individuals motivated to quit (i.e., willing to comply with antagonist treatment).

Opioid antagonism

Based on findings that the opioid and cannabinoid systems can modulate each other, the opioid antagonist naltrexone was evaluated in the squirrel monkey THC self-administration model. In an initial study³⁶, naltrexone did not affect cocaine self-administration, but it consistently decreased THC self-administration on each of the five consecutive days of testing. However, in a later study with a different schedule of reinforcement, the effect of

naltrexone on THC self-administration dissipated after two days of treatment.⁵⁰ In the first study, every 10th lever response produced a THC infusion, and approximately 50 THC infusions could be obtained over the course of each one-hour session. In the second study, every 10th response produced brief presentations of a visual stimulus, but the stimulus was only accompanied by THC infusion once, at the end of the session. So, these two studies differed in both the potential rate of drug delivery and the role of drug associated cues. Thus, the findings suggest that naltrexone can block the reinforcing effects of THC, but may not be effective at blocking the conditioned reinforcing effects of THC-associated cues, which are believed to play a major role in maintaining drug seeking in humans.

Adenosine antagonism

Adenosine A_{2A} receptors form interactive heteromeric complexes with cannabinoid CB₁ receptors in the striatum, and systemic treatment with the A_{2A} antagonist MSX-3 can counteract the motor depressant effects of intrastriatal infusion of the CB₁ agonist WIN 55,212-2 in rats.⁷¹ In squirrel monkeys, a 1 mg/kg dose of MSX-3 shifted the dose-response curve for THC or anandamide self-administration downward, consistent with a decrease in reward, but a 3 mg/kg dose of MSX-3 shifted the curve to the left, consistent with enhanced reward.⁷² It was hypothesized that the opposite effects of the 1 and 3 mg/kg doses of MSX-3 on cannabinoid self-administration were due to MSX-3 acting preferentially at presynaptic A_{2A} receptors at low doses, but at both presynaptic and postsynaptic receptors at higher doses. This hypothesis was strongly supported in a subsequent study using antagonists selective for presynaptic and postsynaptic A_{2A} receptors.⁷³ The presynaptic antagonist SCH-442416 shifted the dose-response curve for THC self-administration to the right, indicating a blockade of THC's rewarding effects, but the post-synaptic antagonist KW-6002 shifted the curve to the left, indicating an enhancement of THC's rewarding effects. These findings indicate that pre-synaptic A_{2A} antagonists like SCH-442416 should be further investigated as potential treatments for cannabis use disorders.

Cholinergic manipulations

The ability of adenosine A_{2A} antagonists to modulate cannabinoid reward are consistent with the hypothesis that activation of CB₁ receptors increases corticostriatal neurotransmission by decreasing cortical GABAergic signaling, which in turn could produce glutamate release and glutamate-dependent dopamine release in the striatum.⁷³ This possibility was further supported by the finding that reward-related effects of cannabinoids (but not cocaine) in rats are decreased by drugs that decrease corticostriatal glutamatergic neurotransmission; these drugs include not only adenosine A_{2A} antagonists but also $\alpha 7$ nicotinic acetylcholine receptor antagonists such as methyllycaconitine. Specifically, methyllycaconitine blocked the interoceptive effects of THC in a drug-discrimination procedure, decreased WIN 55,212-2 self-administration, and decreased THC-induced dopamine release in the shell of the nucleus accumbens in rats.⁷⁴ Unfortunately, antagonists acting directly at $\alpha 7$ nicotinic receptors tend to produce central and peripheral side effects that limit their usefulness as medications. However, the activity of $\alpha 7$ receptors can be decreased, possibly with fewer side effects, by administering an inhibitor of kynurenine 3-monooxygenase (KMO), which enhances endogenous levels of kynurenic acid, a negative allosteric modulator of $\alpha 7$ receptors.

The effects of negative allosteric modulation of $\alpha 7$ receptors were extensively studied in squirrel monkeys and rats by administering the KMO inhibitor, Ro 61-8048.⁷⁵ KMO inhibition decreased WIN 55,212-2 self-administration in rats and THC self-administration in monkeys. Food and cocaine self-administration were not affected, indicating that KMO inhibition did not produce a nonselective impairment of lever-pressing behavior. Treatment with the KMO inhibitor blocked the relapse-like effects induced by re-exposure to THC, WIN 55,212-2, or THC-associated cues after a period of abstinence. Microdialysis experiments in rats indicated that systemic KMO inhibition attenuated the ability of THC to induce dopamine release in the nucleus accumbens shell and VTA. These findings suggest that KMO inhibition could be a viable strategy for treating cannabis use disorders.⁷⁵

Summary

Cannabis and synthetic cannabinoids are increasingly available and increasingly abused. The addictive potential and the seriousness of adverse effects associated with these drugs is less than those associated with some controlled but legal drugs, including prescription opioids, alcohol, and nicotine. However, cannabis abuse disorders (and concomitant psychiatric effects) do occur in substantial numbers of cannabinoid users, and there is a clear need for new and improved treatment options. While prevention and behavioral/psychosocial treatments for these disorders should clearly be emphasized, there should also be efforts to develop effective pharmacotherapies. Research into potential medications for cannabis abuse disorders is still in a very early stage, but some possible molecular targets have been identified. Studies in humans suggest that replacement therapy with CB1-receptor agonists can reduce withdrawal symptoms, and that the antiepileptic gabapentin and the over-the-counter amino acid prodrug N-acetylcysteine might be useful for reducing cannabis use. In animal models, interactions between the endogenous systems that underlie the effects of cannabinoids, opioids, and nicotine suggest that addictive effects of these drugs might be enhanced when they are combined, but also that medications that decrease the activity of any one of these systems might decrease cannabis use. Selective adenosine antagonists also show promise in animal models of cannabinoid use. There is evidence that genetics can affect susceptibility to cannabinoid reward and addiction, and that adolescents are particularly susceptible to cannabinoid-induced addictive effects and lasting cognitive deficits. Finally, as a wider range of synthetic cannabinoids come to be abused, there will continue to be a need for research to learn more about these drugs and to assess their potential for harm.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We dedicate this manuscript to the memory of Dr. Steven R. Goldberg (1941–2014), whose passion for cannabinoid research was an inspiration to us.

Preparation of this manuscript was supported by the Intramural Research Program of the National Institute on Drug Abuse, National Institutes of Health, Department of Health and Human Services.

References

1. Vandrey R, Dunn KE, Fry JA, Girling ER. A survey study to characterize use of Spice products (synthetic cannabinoids). *Drug and alcohol dependence*. 2012; 120:238–41. [PubMed: 21835562]
2. Drug Enforcement Administration, Department of Justice. Schedules of controlled substances: temporary placement of four synthetic cannabinoids into Schedule I. Final order. *Federal Register*. 2014; 79:7577–82. [PubMed: 24605391]
3. Substance Abuse and Mental Health Services Administration. HHS Publication No. (SMA) 14-4863. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2014. Results from the 2013 National Survey on Drug Use and Health: Summary of National Findings, NSDUH Series H-48.
4. Izzo AA, Borrelli F, Capasso R, Di Marzo V, Mechoulam R. Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. *Trends in pharmacological sciences*. 2009; 30:515–27. [PubMed: 19729208]
5. Niesink RJ, van Laar MW. Does Cannabidiol Protect Against Adverse Psychological Effects of THC? *Frontiers in psychiatry*. 2013; 4:130. [PubMed: 24137134]
6. Seigney EL. Is today's marijuana more potent simply because it's fresher? *Drug testing and analysis*. 2013; 5:62–7. [PubMed: 23169764]
7. van Amsterdam J, Brunt T, van den Brink W. The adverse health effects of synthetic cannabinoids with emphasis on psychosis-like effects. *Journal of psychopharmacology*. 2015
8. Spaderna M, Addy PH, D'Souza DC. Spicing things up: synthetic cannabinoids. *Psychopharmacology*. 2013; 228:525–40. [PubMed: 23836028]
9. Castaneto MS, Gorelick DA, Desrosiers NA, Hartman RL, Pirard S, Huestis MA. Synthetic cannabinoids: epidemiology, pharmacodynamics, and clinical implications. *Drug and alcohol dependence*. 2014; 144:12–41. [PubMed: 25220897]
10. Karila L, et al. Acute and long-term effects of cannabis use: a review. *Current pharmaceutical design*. 2014; 20:4112–8. [PubMed: 24001294]
11. Johns A. Psychiatric effects of cannabis. *The British journal of psychiatry: the journal of mental science*. 2001; 178:116–22. [PubMed: 11157424]
12. Hall W. What has research over the past two decades revealed about the adverse health effects of recreational cannabis use? *Addiction*. 2015; 110:19–35. [PubMed: 25287883]
13. Hartman RL, Huestis MA. Cannabis effects on driving skills. *Clinical chemistry*. 2013; 59:478–92. [PubMed: 23220273]
14. Volkow ND, Baler RD, Compton WM, Weiss SR. Adverse health effects of marijuana use. *The New England journal of medicine*. 2014; 370:2219–27. [PubMed: 24897085]
15. Hall W, Degenhardt L. The adverse health effects of chronic cannabis use. *Drug testing and analysis*. 2014; 6:39–45. [PubMed: 23836598]
16. Cadet JL, Bisagno V, Milroy CM. Neuropathology of substance use disorders. *Acta neuropathologica*. 2014; 127:91–107. [PubMed: 24292887]
17. Volkow ND, et al. Decreased dopamine brain reactivity in marijuana abusers is associated with negative emotionality and addiction severity. *Proceedings of the National Academy of Sciences of the United States of America*. 2014; 111:E3149–56. [PubMed: 25024177]
18. Le Strat Y, Dubertret C, Le Foll B. Impact of age at onset of cannabis use on cannabis dependence and driving under the influence in the United States. *Accident; analysis and prevention*. 2015; 76:1–5.
19. Agrawal A, Budney AJ, Lynskey MT. The co-occurring use and misuse of cannabis and tobacco: a review. *Addiction*. 2012; 107:1221–33. [PubMed: 22300456]
20. Colizzi M, et al. Functional genetic variation of the cannabinoid receptor 1 and cannabis use interact on prefrontal connectivity and related working memory behavior. *Neuropsychopharmacology*. 2015; 40:640–9. [PubMed: 25139064]
21. Hughes JR, Fingar JR, Budney AJ, Naud S, Helzer JE, Callas PW. Marijuana use and intoxication among daily users: an intensive longitudinal study. *Addictive behaviors*. 2014; 39:1464–70. [PubMed: 24935797]

22. Haney M, et al. Predictors of marijuana relapse in the human laboratory: robust impact of tobacco cigarette smoking status. *Biological psychiatry*. 2013; 73:242–8. [PubMed: 22939992]
23. Hasin DS, et al. DSM-5 criteria for substance use disorders: recommendations and rationale. *The American journal of psychiatry*. 2013; 170:834–51. [PubMed: 23903334]
24. Cooper ZD, Haney M. Actions of delta-9-tetrahydrocannabinol in cannabis: relation to use, abuse, dependence. *International review of psychiatry (Abingdon, England)*. 2009; 21:104–12.
25. Gorelick DA, et al. Diagnostic criteria for cannabis withdrawal syndrome. *Drug and alcohol dependence*. 2012; 123:141–7. [PubMed: 22153944]
26. Haney M. The marijuana withdrawal syndrome: diagnosis and treatment. *Current psychiatry reports*. 2005; 7:360–6. [PubMed: 16216154]
27. Allsop DJ, et al. Quantifying the clinical significance of cannabis withdrawal. *PloS one*. 2012; 7:e44864. [PubMed: 23049760]
28. Goldman M, et al. Reward-related brain response and craving correlates of marijuana cue exposure: a preliminary study in treatment-seeking marijuana-dependent subjects. *Journal of addiction medicine*. 2013; 7:8–16. [PubMed: 23188041]
29. Balter RE, Cooper ZD, Haney M. Novel Pharmacologic Approaches to Treating Cannabis Use Disorder. *Current addiction reports*. 2014; 1:137–43. [PubMed: 24955304]
30. Budney AJ, Roffman R, Stephens RS, Walker D. Marijuana dependence and its treatment. *Addiction science & clinical practice*. 2007; 4:4–16. [PubMed: 18292704]
31. Levin FR, Mariani JJ, Brooks DJ, Pavlicova M, Cheng W, Nunes EV. Dronabinol for the treatment of cannabis dependence: a randomized, double-blind, placebo-controlled trial. *Drug and alcohol dependence*. 2011; 116:142–50. [PubMed: 21310551]
32. Haney M, Cooper ZD, Bedi G, Vosburg SK, Comer SD, Foltin RW. Nabilone decreases marijuana withdrawal and a laboratory measure of marijuana relapse. *Neuropsychopharmacology*. 2013; 38:1557–65. [PubMed: 23443718]
33. Huggins JP, Smart TS, Langman S, Taylor L, Young T. An efficient randomised, placebo-controlled clinical trial with the irreversible fatty acid amide hydrolase-1 inhibitor PF-04457845, which modulates endocannabinoids but fails to induce effective analgesia in patients with pain due to osteoarthritis of the knee. *Pain*. 2012; 153:1837–46. [PubMed: 22727500]
34. Huestis MA, et al. Single and multiple doses of rimonabant antagonize acute effects of smoked cannabis in male cannabis users. *Psychopharmacology*. 2007; 194:505–15. [PubMed: 17619859]
35. Le Foll B, Gorelick DA, Goldberg SR. The future of endocannabinoid-oriented clinical research after CB1 antagonists. *Psychopharmacology*. 2009; 205:171–4. [PubMed: 19300982]
36. Justinova Z, Tanda G, Munzar P, Goldberg SR. The opioid antagonist naltrexone reduces the reinforcing effects of Delta 9 tetrahydrocannabinol (THC) in squirrel monkeys. *Psychopharmacology*. 2004; 173:186–94. [PubMed: 14668977]
37. Cooper ZD, Haney M. Opioid antagonism enhances marijuana's effects in heavy marijuana smokers. *Psychopharmacology*. 2010; 211:141–8. [PubMed: 20490465]
38. Haney M, Hart CL, Vosburg SK, Comer SD, Reed SC, Foltin RW. Effects of THC and lofexidine in a human laboratory model of marijuana withdrawal and relapse. *Psychopharmacology*. 2008; 197:157–68. [PubMed: 18161012]
39. Mason BJ, et al. A proof-of-concept randomized controlled study of gabapentin: effects on cannabis use, withdrawal and executive function deficits in cannabis-dependent adults. *Neuropsychopharmacology*. 2012; 37:1689–98. [PubMed: 22373942]
40. Gray KM, et al. A double-blind randomized controlled trial of N-acetylcysteine in cannabis-dependent adolescents. *The American journal of psychiatry*. 2012; 169:805–12. [PubMed: 22706327]
41. Marshall K, Gowing L, Ali R, Le Foll B. Pharmacotherapies for cannabis dependence. *The Cochrane database of systematic reviews*. 2014; 12:Cd008940. [PubMed: 25515775]
42. Fratta W, Fattore L. Molecular mechanisms of cannabinoid addiction. *Current opinion in neurobiology*. 2013; 23:487–92. [PubMed: 23490548]
43. Hoffman AF, Lupica CR. Synaptic targets of Delta9-tetrahydrocannabinol in the central nervous system. *Cold Spring Harbor perspectives in medicine*. 2013; 3

44. Covey DP, Wenzel JM, Cheer JF. Cannabinoid modulation of drug reward and the implications of marijuana legalization. *Brain research*. 2014
45. Tanda G, Munzar P, Goldberg SR. Self-administration behavior is maintained by the psychoactive ingredient of marijuana in squirrel monkeys. *Nature neuroscience*. 2000; 3:1073–4.
46. Martellotta MC, Cossu G, Fattore L, Gessa GL, Fratta W. Self-administration of the cannabinoid receptor agonist WIN 55,212-2 in drug-naive mice. *Neuroscience*. 1998; 85:327–30. [PubMed: 9622233]
47. Lefever TW, Marusich JA, Antonazzo KR, Wiley JL. Evaluation of WIN 55,212-2 self-administration in rats as a potential cannabinoid abuse liability model. *Pharmacology, biochemistry, and behavior*. 2014; 118:30–5.
48. Mendizabal V, Zimmer A, Maldonado R. Involvement of kappa/dynorphin system in WIN 55,212-2 self-administration in mice. *Neuropsychopharmacology*. 2006; 31:1957–66. [PubMed: 16292318]
49. Justinova Z, Tanda G, Redhi GH, Goldberg SR. Self-administration of delta9-tetrahydrocannabinol (THC) by drug naive squirrel monkeys. *Psychopharmacology*. 2003; 169:135–40. [PubMed: 12827345]
50. Justinova Z, et al. Blockade of THC-seeking behavior and relapse in monkeys by the cannabinoid CB(1)-receptor antagonist rimonabant. *Neuropsychopharmacology*. 2008; 33:2870–7. [PubMed: 18305459]
51. Justinova Z, Solinas M, Tanda G, Redhi GH, Goldberg SR. The endogenous cannabinoid anandamide and its synthetic analog R(+)-methanandamide are intravenously self-administered by squirrel monkeys. *The Journal of neuroscience*. 2005; 25:5645–50. [PubMed: 15944392]
52. Justinova Z, Yasar S, Redhi GH, Goldberg SR. The endogenous cannabinoid 2-arachidonoylglycerol is intravenously self-administered by squirrel monkeys. *The Journal of neuroscience*. 2011; 31:7043–8. [PubMed: 21562266]
53. Spano MS, Fattore L, Cossu G, Deiana S, Fadda P, Fratta W. CB1 receptor agonist and heroin, but not cocaine, reinstate cannabinoid-seeking behaviour in the rat. *Br J Pharmacol*. 2004; 143:343–50. [PubMed: 15339858]
54. Deiana S, et al. Strain and schedule-dependent differences in the acquisition, maintenance and extinction of intravenous cannabinoid self-administration in rats. *Neuropharmacology*. 2007; 52:646–54. [PubMed: 17098261]
55. Lecca D, Cacciapaglia F, Valentini V, Di Chiara G. Monitoring extracellular dopamine in the rat nucleus accumbens shell and core during acquisition and maintenance of intravenous WIN 55,212-2 self-administration. *Psychopharmacology*. 2006; 188:63–74. [PubMed: 16850116]
56. Lepore M, Vorel SR, Lowinson J, Gardner EL. Conditioned place preference induced by delta 9-tetrahydrocannabinol: comparison with cocaine, morphine, and food reward. *Life sciences*. 1995; 56:2073–80. [PubMed: 7776834]
57. Carvalho AF, Reyes AR, Sterling RC, Unterwald E, Van Bockstaele EJ. Contribution of limbic norepinephrine to cannabinoid-induced aversion. *Psychopharmacology*. 2010; 211:479–91. [PubMed: 20602088]
58. Hyatt WS, Fantegrossi WE. Delta9-THC exposure attenuates aversive effects and reveals appetitive effects of K2/‘Spice’ constituent JWH-018 in mice. *Behavioural pharmacology*. 2014; 25:253–7. [PubMed: 24625557]
59. Maldonado R. Study of cannabinoid dependence in animals. *Pharmacology & therapeutics*. 2002; 95:153–64. [PubMed: 12182962]
60. Solinas M, Scherma M, Tanda G, Wertheim CE, Fratta W, Goldberg SR. Nicotinic facilitation of delta9-tetrahydrocannabinol discrimination involves endogenous anandamide. *The Journal of pharmacology and experimental therapeutics*. 2007; 321:1127–34. [PubMed: 17351107]
61. Solinas M, Zangen A, Thiriet N, Goldberg SR. Beta-endorphin elevations in the ventral tegmental area regulate the discriminative effects of Delta-9-tetrahydrocannabinol. *The European journal of neuroscience*. 2004; 19:3183–92. [PubMed: 15217374]
62. Zangen A, Solinas M, Ikemoto S, Goldberg SR, Wise RA. Two brain sites for cannabinoid reward. *The Journal of neuroscience*. 2006; 26:4901–7. [PubMed: 16672664]

63. Aceto MD, Scates SM, Lowe JA, Martin BR. Dependence on delta 9-tetrahydrocannabinol: studies on precipitated and abrupt withdrawal. *The Journal of pharmacology and experimental therapeutics*. 1996; 278:1290–5. [PubMed: 8819514]
64. Marusich JA, Lefever TW, Antonazzo KR, Craft RM, Wiley JL. Evaluation of sex differences in cannabinoid dependence. *Drug and alcohol dependence*. 2014; 137:20–8. [PubMed: 24582909]
65. Beardsley PM, Martin BR. Effects of the cannabinoid CB(1) receptor antagonist, SR141716A, after Delta(9)-tetrahydrocannabinol withdrawal. *European journal of pharmacology*. 2000; 387:47–53. [PubMed: 10633159]
66. McMahon LR. Discriminative stimulus effects of the cannabinoid CB1 antagonist SR 141716A in rhesus monkeys pretreated with Delta9-tetrahydrocannabinol. *Psychopharmacology*. 2006; 188:306–14. [PubMed: 16953389]
67. Solinas M, Panlilio LV, Goldberg SR. Exposure to delta-9-tetrahydrocannabinol (THC) increases subsequent heroin taking but not heroin's reinforcing efficacy: a self-administration study in rats. *Neuropsychopharmacology*. 2004; 29:1301–11. [PubMed: 15039767]
68. Panlilio LV, Solinas M, Matthews SA, Goldberg SR. Previous exposure to THC alters the reinforcing efficacy and anxiety-related effects of cocaine in rats. *Neuropsychopharmacology*. 2007; 32:646–57. [PubMed: 16738542]
69. Panlilio LV, Zanettini C, Barnes C, Solinas M, Goldberg SR. Prior exposure to THC increases the addictive effects of nicotine in rats. *Neuropsychopharmacology*. 2013; 38:1198–208. [PubMed: 23314220]
70. Degenhardt L, et al. Does the 'gateway' matter? Associations between the order of drug use initiation and the development of drug dependence in the National Comorbidity Study Replication. *Psychological medicine*. 2009; 39:157–67. [PubMed: 18466664]
71. Carriba P, et al. Striatal adenosine A2A and cannabinoid CB1 receptors form functional heteromeric complexes that mediate the motor effects of cannabinoids. *Neuropsychopharmacology*. 2007; 32:2249–59. [PubMed: 17356572]
72. Justinova Z, et al. Reinforcing and neurochemical effects of cannabinoid CB1 receptor agonists, but not cocaine, are altered by an adenosine A2A receptor antagonist. *Addiction biology*. 2011; 16:405–15. [PubMed: 21054689]
73. Justinova Z, Redhi GH, Goldberg SR, Ferre S. Differential effects of presynaptic versus postsynaptic adenosine A2A receptor blockade on Delta9-tetrahydrocannabinol (THC) self-administration in squirrel monkeys. *The Journal of neuroscience*. 2014; 34:6480–4. [PubMed: 24806674]
74. Solinas M, et al. Nicotinic alpha 7 receptors as a new target for treatment of cannabis abuse. *The Journal of neuroscience*. 2007; 27:5615–20. [PubMed: 17522306]
75. Justinova Z, et al. Reducing cannabinoid abuse and preventing relapse by enhancing endogenous brain levels of kynurenic acid. *Nature neuroscience*. 2013; 16:1652–61.

Figure 1.

Generalized scheme of the sites of THC action throughout the mammalian central nervous system (Originally published in Hoffman and Lupica⁴³). CB1 receptors are shown on both excitatory glutamatergic (Glut.) and inhibitory (GABA) axon terminals, and in many cases these synapses are formed with neurons providing output (Output neuron) of central nuclei (e.g., hippocampal pyramidal neurons and medium spiny neurons in the NAc and dorsal striatum). These presynaptic CB1 receptors can be activated by the release of endocannabinoids (eCB) on depolarization of postsynaptic neurons or by exogenous agonists such as THC. Also shown is the chemical structure of THC (inset). *Reproduced with permission of Cold Spring Harbor Laboratory Press.*

Figure 2.

Dose-response curves for self-administration of various intravenous drugs in squirrel monkeys. Ten lever-press responses (FR10) were required for each injection, and there was a 60-s time-out period after each injection, during which responses had no programmed consequences. The numbers of injections per 1-hr session are shown as a function of the dose of THC, the endogenous cannabinoids anandamide and 2-arachidonoylglycerol (2-AG), nicotine, cocaine, or methamphetamine when offered as intravenous solutions. Each point represents mean $\pm$ SEM from three to four monkeys. Data previously unpublished as shown, obtained using procedures that parallel those described in studies by Justinova et al. 36, 49, 51, 52, 72, 73, 75

Table 1**DSM-V Diagnostic Criteria for Cannabis Use Disorder**

A problematic pattern of cannabis use leading to clinically significant impairment or distress, as manifested by at least two of the following, occurring within a 12-month period:

- 1** Cannabis is often taken in larger amounts or over a longer period than was intended.
 - 2** There is a persistent desire or unsuccessful efforts to cut down or control cannabis use.
 - 3** A great deal of time is spent in activities necessary to obtain cannabis, use cannabis, or recover from its effects.
 - 4** Craving, or a strong desire or urge to use cannabis.
 - 5** Recurrent cannabis use resulting in a failure to fulfill major role obligations at work, school, or home.
 - 6** Continued cannabis use despite having persistent or recurrent social or interpersonal problems caused or exacerbated by the effects of cannabis.
 - 7** Important social, occupational, or recreational activities are given up or reduced because of cannabis use.
 - 8** Recurrent cannabis use in situations in which it is physically hazardous.
 - 9** Cannabis use is continued despite knowledge of having a persistent or recurrent physical or psychological problem that is likely to have been caused or exacerbated by cannabis.
 - 10** Tolerance, as defined by either of the following:
 - a.** A need for markedly increased amounts of cannabis to achieve intoxication or desired effect.
 - b.** Markedly diminished effect with continued use of the same amount of cannabis.
 - 11** Withdrawal, as manifested by either of the following:
 - a.** The characteristic withdrawal syndrome for cannabis (refer to Criteria A and B of the criteria set for cannabis withdrawal, Table 2).
 - b.** Cannabis (or a closely related substance) is taken to relieve or avoid withdrawal symptoms.
-

Specify current severity:

Mild: Presence of 2–3 symptoms.

Moderate: Presence of 4–5 symptoms.

Severe: Presence of 6 or more symptoms.

Table 2**DSM-V Diagnostic Criteria for Cannabis Withdrawal**

-
- A.** Cessation of cannabis use that has been heavy and prolonged (i.e., usually daily or almost daily use over a period of at least a few months).
- B.** Three (or more) of the following signs and symptoms develop within approximately 1 week after Criterion A:
1. Irritability, anger, or aggression.
 2. Nervousness or anxiety.
 3. Sleep difficulty (e.g., insomnia, disturbing dreams).
 4. Decreased appetite or weight loss.
 5. Restlessness.
 6. Depressed mood.
 7. At least one of the following physical symptoms causing significant discomfort: abdominal pain, shakiness/tremors, sweating, fever, chills, or headache.
- C.** The signs or symptoms in Criterion B cause clinically significant distress or impairment in social, occupational, or other important areas of functioning.
-

The signs or symptoms are not attributable to another medical condition and are not better explained by another mental disorder, including intoxication or withdrawal from another substance